Abstract Fibroblast Growth Factor 23 (FGF23), a known regulator of phosphate homeostasis, is produced by cells residing in bone, namely, osteocytes, to target a distant organ, the kidney. Elevated FGF23 levels have recently been found systemically and in osteocytes in patients and animal models of chronic kidney disease. Associations between serum FGF23 level and vascular dysfunction, vascular calcification, and increased risk of cardiovascular disease have also been observed. In this review we discuss FGF23 expression in osteocytes and the potential means to regulate expression and function of this protein at the osteocyte level.
Introduction: the osteocyte and fibroblast growth factor 23
Osteocytes are cells embedded in the mineralized bone matrix, connected to each other and cells outside the bone through a bone fluid-filled lacunocanalicular system (Figs. 1, 2, 3) [1, 2] . In the adult skeleton they comprise over 90-95 % of all bone cells, as compared to osteoblasts which make bone (<5 %) and osteoclasts which resorb bone (>1 %). Osteocytes, unlike most cells in the body, are long-lived, up to decades within the bone matrix. It has long been thought that the major function of osteocytes is to respond to mechanical strain with biochemical signals that regulate osteoblast and osteoclast activity [3] . However, within recent years it has been discovered that osteocytes are also secretory cells that can target tissues other than bone [4] . These cells are multifunctional, acting as mechanosensors and communicators, orchestrators of bone modeling and remodeling, and regulators of calcium and phosphate homeostasis and functioning as endocrine cells by sending signals to distant tissues. This review will focus on the role of osteocytes as endocrine cells through the production of fibroblast growth factor 23 (FGF23). Since its identification in 2000 in the ventrolateral thalamic nucleus of the brain [5] , FGF23 has actually been found to be most highly expressed in bone, predominantly in the osteocyte [6] [7] [8] . FGF23 is not normally expressed at high levels in osteocytes but its expression dramatically increases in osteocytes of patients with hypophosphatemic rickets [9] and those with chronic kidney disease (CKD) [10] .
FGF23 is an important hormone in regulating serum phosphate levels. One mechanism by which FGF23 does this is by reducing expression and/or insertion of the sodium-phosphate transporters (type IIa and IIc) within renal proximal tubular membranes so that more phosphate is excreted [11] . A second mechanism is by inhibiting renal 1-α-hydroxylase expression (and promoting 24-hydroxylase expression), which reduces 1,25-dihydroxyvitamin [1,25(OH) 2 D] levels and therefore reduces the amount of phosphate absorption from the gut and bone [12] . These actions are thought to be the main reasons that hypophosphatemia occurs in certain disease states with elevated FGF23 levels. FGF23 also is involved in altering parathyroid hormone (PTH) levels. Specifically, it has been shown that FGF23 can inhibit the synthesis of PTH mRNA in the rat [13] . However, the significance of this in humans, especially those with CKD, is a little more difficult to interpret. FGF23 causes a decrease in 1,25(OH) 2 D, and a low level of 1,25 (OH) 2 D can cause an up-regulation of PTH. In the setting of CKD there is a chronically elevated serum phosphate level which induces an increase in both PTH and FGF23. In addition, in hyperparathyroidism secondary to renal failure, it has been proposed the parathyroid becomes less sensitive to FGF23 signaling by down-regulation of FGFRs and Klotho, which further complicates the interaction [14] .
FGF23 primarily mediates these actions on the kidney and parathyroid through FGF receptor (FGFR) subtypes 1, 3, 4 [15, 16] . Typically, it has been thought that FGF23 also needs the transmembrane co-receptor Klotho to help increase the binding affinity of FGF23 to FGFRs [17, 18] . The osteocyte itself expresses FGFRs, and the low expression of Klotho and signaling through FGFRs are thought to be involved in the regulation of FGF23 expression, as will be discussed later in this review.
Regulation of release of FGF23 by the osteocyte
The release of FGF23 is one of the main means whereby young osteocytes and mature osteocytes regulate mineralization and phosphate homeostasis. Osteocytes also appear to regulate FGF23 signaling and bio-mineralization through molecules such as the phosphate-regulating gene with homologies to endopeptidases on X chromosome (PHEX), dentin matrix protein-1 (DMP1), and matrix extracellular phospho-glycoprotein (MEPE) [19] , which are all highly expressed in osteocytes [20] [21] [22] . X-linked hypophosphatemic rickets is due to mutations in Phex [20] , and autosomal recessive hypophosphatemic rickets is due to mutations in Dmp1 [7] . PHEX is a metalloendoproteinase with an unclear function, but it clearly plays a role in phosphate homeostasis and bone mineralization. DMP1 is also essential for mineralization, and both Dmp1 and Phex expression are markers of early osteocytes. In the absence of either functional Dmp1 or Phex, FGF23 is dramatically elevated in the osteocyte and in the circulation, leading to phosphate excretion by the kidney, thereby reducing circulating phosphate and resulting in osteomalacia and rickets. Loss-of-function mutations and knock-out murine models have been made for Phex, Dmp1, and Mepe [7, 20, [23] [24] [25] . Dmp1 null mice have a similar phenotype to 'Hyp' mice carrying a Phex mutation, i.e., osteomalacia and rickets, due to elevated FGF23 levels in osteocytes [7] , whereas the Mepe nulls have increased bone mass [25] .
The exact mechanism(s) by which DMP1 and PHEX regulate FGF23 are yet to be determined; however, recent data suggest that their inhibitory effects are mediated by FGFR signaling in the osteocyte [26] . Dmp1-null and Hyp mouse models show enhanced FGFR signaling compared to wild-type control mice, and the inhibition of FGFR signaling results in a reduction of FGF23 in the bone marrow stromal cells from both mouse models. Martin et al. [26] concluded that it was likely not FGF23 acting back on the FGFR itself but on some other FGFR-mediated pathway. These findings indicate that FGFRs play a role in endocrine signaling through the osteocyte, acting on organs such as the kidney, but that they also play an autocrine/paracrine role on the osteocyte itself.
The effects of MEPE on FGF23 and matrix mineralization are complex due to the release of an acidic serine aspartate-rich MEPE-associated motif (ASARM) from the C-terminus of MEPE. This 19-amino acid peptide is known to be a potent inhibitor of mineralization in vivo [27, 28] , and the absence of this peptide in MEPE-null mice may be the reason these mice have increased bone [25] . The binding of PHEX to MEPE prevents both its proteolytic degradation and the release of the ASARM peptide [29] , thereby preventing down-regulation of FGF23. If the ASARM peptide is generated, it binds specifically to PHEX in vitro to inhibit PHEX enzymatic activity [9] , which results in up-regulation of FGF23 expression. In addition, the phosphorylated MEPE-ASARM peptide itself is a substrate for PHEX, with cleavage of ASARM by PHEX neutralizing its activity and restoring mineralization [30] . This is a very complex regulatory system that requires further study.
In addition to being regulated by DMP1, PHEX, and MEPE, 1,25(OH) 2 D induces expression of FGF23 in the osteocyte [31, 32] , suggesting a negative feedback system. In addition to 1,25(OH) 2 D, PTH may also directly regulate FGF23 levels. The infusion of PTH in mice was found to cause increased FGF23 mRNA expression in the calvaria and increased serum FGF23 [33] . PTH was also shown to up-regulate FGF23 mRNA expression in UMR106 cells. Rhee and colleagues observed an increase in FGF23 expression in osteocytes of transgenic mice with constitutive activation of the PTH receptor (PTHR1) in osteocytes under control of the DMP1 promoter [34] .
Biologically active FGF23 is not only regulated at the gene level, but also at the protein level. FGF23 activity is regulated by the extent of glycosylation and proteolytic processing. Intact FGF23 (32-35 kDa) is biologically active, whereas the c-terminal form (15-17 kDa) is inactiveyet both are present in the circulation, emphasizing the importance of assays that can make a distinction between the two forms [35] . The c-terminal form may block the bioactivity of the intact form [36] . Glycosylation of intact FGF23 protects against furin-mediated cleavage to generate the c-terminal form. Therefore, the relative expression of the glycosyl transferase and protease (thought to be furin) determines the ratio of intact/cleaved FGF23. It also appears that iron levels can regulate the levels of cleaved FGF23, while not affecting those of intact FGF23 [37] , but it is not yet clear how iron deficiency can increase a product of the intact protein without affecting intact protein levels. Hypophosphatemia and familial tumoral calcinosis are examples of conditions caused by high and low levels, respectively, of intact FGF23. In fibrous dysplasia, high levels of both intact and cleaved FGF23 are detected, suggesting that the cleaved form neutralizes the biological activity of the intact FGF23 [38] . It has recently been shown that with renal disease only intact-and no cleaved-FGF23 is present. As FGF23 is elevated in osteocytes in hypophosphatemic rickets and CKD, it is assumed that little if any of the cleaved form of FGF23 is being generated. To date, it is not known how these processes are being regulated in the osteocyte.
The location of the osteocytes that release FGF23 may be different in different disease states. In mouse models of hereditary hypophosphatemia, FGF23 is typically released by osteocytes of both cortical and trabecular bone [31, 39] . However, differences were found in a study conducted on the Col4a3 null mouse, which is a model of human autosomal-recessive Alport disease in which there is progressive renal failure [40] . In this study, FGF23 was primarily found to be expressed in trabecular osteocytes, leading these authors to conclude that there may be differences in FGF23 release in CKD versus other genetic forms of hypophosphatemia. In addition, Stubbs et al. [40] observed that significant increases in Fgf23 gene expression in the bone did not occur until later stages of CKD. Since FGF23 becomes elevated very early on in CKD and since the major site of FGF23 production is from the osteocyte, it is possible that the post-transcriptional processing, excretion, or breakdown of FGF23 is altered during the early stages of CKD.
Bone-heart crosstalk
While it is well documented that FGF23 plays an important role as an endocrine agent in regulating phosphate and mineralization through organs such as the kidney and parathyroid, there is new evidence that FGF23 may also be important for targeting other organs, such as the heart and vasculature. It is well known that the major cause of morbidity and mortality with CKD is heart disease, and recent clinical studies have found an independent association between serum FGF23 levels and left ventricular hypertrophy in CKD patients [41] [42] [43] [44] [45] . All four isoforms have been detected in cardiomyocytes [46, 47] , which we have also confirmed in preliminary data from isolated mouse ventricular cardiomyocytes in our laboratory. Therefore, it has logically been hypothesized that FGF23 may directly induce cardiac hypertrophy. To date, however, there is only one study that has directly tested this possibility. Faul et al. [46] observed that 48 h of treatment with 10-100 ng/ml FGF23 increased the cell size of isolated neonatal rat cardiomyocytes blocked by a pan-FGF receptor inhibitor. Furthermore, in vivo intramyocardial injections of FGF23 increased left ventricular wall thickness by day 7. Lastly, using a model of CKD (5/6 nephrectomized mouse) that has elevated serum FGF23, these authors found that left ventricular hypertrophy was reduced in those animals that received the pan-FGF receptor inhibitor. Interestingly, while klotho has been detected in the sinoatrial (SA) node, it has not been found in the ventricles [46, 48] . Therefore, cardiac hypertrophy may be an example of FGF23 acting independent of this coreceptor that was thought to be needed for function. It is possible that FGF23 may activate FGFRs without the need for Klotho when serum FGF23 concentrations are at a high level, such as during CKD. In addition, it still remains to be elucidated which subtype of FGFR mediates the cardiac hypertrophic effects or if multiple FGFR subtypes work in concert, as has been proposed for FGF23 actions on the kidney [49] . Additional research will be required to fully understand the molecular mechanisms and important consequences for direct FGF23 actions on the myocardium.
There are additional clinical reports of associations of FGF23 serum levels with vascular dysfunction [43, 44] , vascular calcification [50] , and increased risk of cardiovascular disease [51] . While these correlations are likely the result of phosphate handling and disease progression, it remains to be seen if there is also a direct effect of FGF23 on vascular cells. Taken as a whole, these findings in the cardiovascular system suggest that the effect of FGF23 released by osteocytes may be even more complex than that of a hormone involved in phosphate handling, bone disorders, or a marker of kidney disease.
All these findings have raised the question of whether FGF23 is a marker or inducer of renal and cardiovascular pathologies [52, 53] . This is especially significant during the early stages of kidney dysfunction when FGF23 levels rise while the levels of calcium, phosphate, and PTH have not yet significantly changed. FGF23 causes a reduction of 1,25 (OH) 2 D early on in CKD, which could trigger the bone deficiencies observed with the disease. FGF23 could also be altering phosphate transporters in vascular cells, predisposing to calcification and vascular dysfunction [54] . Finally, FGF23 could be altering signaling in cardiac myocytes to set the stage for pathological hypertrophy. However, there are many additional questions, such as why do other diseases with elevated FGF23 levels (such as X-linked hypophosphatemia and autosomal recessive hypophosphatemic rickets) not present an overt cardiovascular phenotype. It is possible that FGF23 is working in concert with other factors specific in the setting of CKD to cause renal and cardiovascular changes. It has recently been hypothesized that disruptions in specific interactions between vitamin D, FGF23, Klotho, and the renin-angiotensinaldosterone system during CKD contribute to disease progression [55] .
Targeted treatment
If FGF23 is found to directly or indirectly induce these organ changes, the osteocyte release of FGF23 will assume the position of a prime target for therapeutic intervention in CKD as well as hypophosphatemia. Efforts are underway to target or reduce the levels of active FGF23. Treatment with FGF23 antibody was found to restore serum phosphate levels in the Hyp mouse model and correct the osteomalacic phenotype [56] , and treatment of Dmp-1-null mice with FGF23 antibody ameliorated the bone defects by increasing the levels of circulating phosphate [57] . Since the potential actions of FGF23 may extend to the cardiovascular system and beyond, treatments targeting FGF23 provide significant therapeutic potential, not only for bone disease but potentially for other chronic diseases.
In summary, the osteocyte lacunocanalicular system functions as an endocrine organ regulating phosphate metabolism through the production of FGF23. Understanding the interactions of osteocyte factors and their targets should lead to insight into diseases of hyper-and hypophosphatemia, diseases of the cardio-vascular system, and chronic kidney disease.
